Charity investor the Wellcome Trust has launched Syncona Partners, an investment subsidiary managing a £200m ($329m) evergreen fund. Previously announced as Project Sigma by the Trust in March 2012, Syncona will be focused on supporting development of sustainable healthcare businesses. The UK-based fund will invest globally, with investments ranging from between £1m to £20m. Syncona will invest at both early and late stage, and as a lead investor or as part of a syndicate. The company has already added two university-linked businesses to its portfolio: life sciences firm Cambridge Epigenetix and Oxford spin-out NightstaRx, which is focused on the development of treatments for degenerative eye conditions. Martin Murphy, chief executive at Syncona, said: “We expect to play our part in building successful businesses based upon innovation within the life science and healthcare industry. We very much look forward to working with entrepreneurs, leading academics and inventors to build success stories in the UK, Europe and beyond.” At the time of the initial announcement, Sir Mark Walport, director of the Wellcome Trust, said: “The Wellcome Trust is known as an investor that takes a long-term view. Sigma will extend this successful approach to direct investments in emerging healthcare technologies, to give small and medium-sized companies the support they require to fulfil their potential. This important investment opportunity will help the Trust to fulfil its vision of achieving extraordinary improvements in health, by generating returns that can be used to fund the work of outstanding researchers in the biomedical sciences and the medical humanities.”
Wellcome Trust’s £200m evergreen fund comes to life
Jan 30, 2014 •
LEADERSHIP SOCIETY
Informing, connecting, and transforming the global corporate venture capital ecosystem.The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Halo has researchers on speed dial for corporates
Halo has researchers on speed dial for corporates
How does a corporate find the right university researcher or startup when it's trying to solve a critical problem? Halo has the answer.
How Basel supercharged its spinout rate
How Basel supercharged its spinout rate
Basel has quietly built a life sciences ecosystem that’s becoming hard to ignore.
Crumbling system, fragile lives: can spinouts help in the senior care crisis?
Crumbling system, fragile lives: can spinouts help in the senior care crisis?
From a chest-worn device to help with Parkinson's symptoms to stress measuring socks — here are the spinouts providing support for senior citizens.
Events
Webinar: Innovate to heal - What does the hospital of the future look like?
Apr 10, 2024
Online
Online
Events
GCV Institute: Landing the Value of Corporate Venturing
May 6 -
May 9, 2024
Online
May 9, 2024
Online
Events
GCV Institute: CVC Investment Programs
May 21 -
May 22, 2024
Online
May 22, 2024
Online
Events
GCV Symposium 2024
Jun 24 -
Jun 26, 2024
London (UK)
Jun 26, 2024
London (UK)
Events
Corporate Venture in Brasil 2024 – International Delegation to Brazil
Oct 28 -
Oct 30, 2024
São Paulo (Brazil)
Oct 30, 2024
São Paulo (Brazil)
Top News
test reg